April 26th 2024
Cellular therapies are an effective option in hematologic malignancies but have been slower to develop in AML, but identifying new targets paves the way for evolving treatments.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Natural Killer Cell Proliferation Achieved in MDS/AML With Novel TriKE
December 6th 2020Treatment with a novel tri-specific natural killer cell engager agent led to natural killer cell proliferation across dose levels in patients with high-risk myelodysplastic syndromes and acute myeloid leukemia.
Read More
HRQoL Maintained With Oral Azacitidine Along With OS and RFS Improvement in AML
December 6th 2020Azacitidine administered orally to patients with acute myeloid leukemia demonstrated significant improvements in overall survival and relapse-free survival while sustaining the health-related quality of life compared with placebo.
Read More
Novel RARα Agonist Combo Induces Clinical Activity in Heavily Pretreated R/R AML
December 6th 2020The addition of the oral selective RARα agonist SY-1425 to azacitidine induced clinical activity as treatment of patients with heavily pretreated relapsed/refractory acute myeloid leukemia with RARA positivity.
Read More
Survival Outcome Influenced by Racial and Ethnic Related Socioeconomic Disparities in AML
December 5th 2020Significant disparities between survival outcomes of non-Hispanic white, non-Hispanic black, and Hispanic patients with acute myeloid leukemia in the Chicago metropolitan area were seen with census tract socioeconomic status information.
Read More
Prolonged Survival Seen With Azacitadine After Induction, Consolidation Therapy in AML
December 5th 2020Patients with acute myeloid leukemia in first remission regardless of the number of rounds of prior consolidation therapy had significantly prolonged overall survival and relapse-free survival with azacitidine.
Read More
The Possibilities in AML With the FDA Approval of Azacitidine and Venetoclax
November 16th 2020Brain A. Jonas, MD, discusses the future of treatment for older patients with acute myeloid leukemia, now that the FDA has granted approval to azacitidine plus venetoclax for patients aged 75 years or older.
Watch
Azacitidine/Venetoclax Represents New Gold Standard for Older Patients with Treatment-Naïve AML
November 13th 2020In an interview with Targeted Oncology following the announcement of the FDA approval of azacitidine plus venetoclax in older patients with acute myeloid leukemia, Brian Jonas, MD, provided insight on the VILAE-A study results. He also gave expert advice on how to approach treating older patients with acute myeloid leukemia in every day practice.
Read More
New ASH Guidelines Highlight a Call to Action for Treatment of Older AML Patients
October 20th 2020New guidelines from he American Society of Hematology for treating newly diagnosed acute myeloid leukemia in older patients recommend intensive antileukemic therapies over more conservative approaches.
Read More
FDA Approves Venetoclax Plus LDAC For Older Patients With Newly Diagnosed AML
October 16th 2020The FDA granted approval to venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine, a regimen known as LDAC, as treatment of adults patients with aged 75 years or older with newly-diagnosed acute myeloid leukemia or who have comorbidities precluding intensive induction chemotherapy.
Read More
CC-486 Constitutes Standard of Care for Subset of Patients with AML
September 5th 2020In an interview with Targeted Oncology Guillermo Garcia-Manero, MD, discussed the key findings from the QUAZAR AML-001 study and the importance of the FDA approval of CC-486 in post-remission acute myeloid leukemia.
Read More
FDA Approves CC-486 as Maintenance Therapy in Acute Myeloid Leukemia
September 1st 2020The FDA granted approval to the oral hypomethylating agent, CC-486 (azacitidine tablets, Onureg), as a maintenance treatment for adult patients with acute myeloid leukemia who achieved a first complete remission or with incomplete blood count recovery after intensive induction chemotherapy and who are unable to complete intensive curative therapy.
Read More
Enasidenib Misses Primary End Point, Appears Safe in Phase 3 Study of R/R Acute Myeloid Leukemia
August 25th 2020Overall survival was not improvement with the combination of enasidenib and best supportive care compared with conventional care regimens when administered to patients relapsed/refractory IDH2-positive acute myeloid leukemia.
Read More
FDA Grants Fast Track Designation to BST-236 for Older Adults With Acute Myeloid Leukemia
August 4th 2020The FDA has granted a Fast Track designation to BST-236 for the treatment of patients with acute myeloid leukemia who are 75 years or older or have comorbidities that preclude the use of intensive induction chemotherapy.
Read More
Treatment Landscape for Acute Myeloid Leukemia Appears Hopeful for Patients
July 31st 2020Eunice Wang, MD, discusses the excitement she has experienced in the treatment landscape of acute myeloid leukemia over the last several years due to the number of new treatment options approved by the FDA.
Watch
Sorafenib Maintenance May Prevent Recurrence After Transplant in FLT3-ITD+ AML
July 21st 2020The risk of relapse or death was reduced by 61% with sorafenib maintenance compared with placebo following allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD–positive acute myeloid leukemia.
Read More
Expansion of AML Treatment Landscape Underscores Importance of Molecular Testing
July 17th 2020In an interview with Targeted Oncology, Naval G. Daver, MD, discussed the current treatment landscape for acute myeloid leukemia and how he goes about sequencing the available agents when he treats patients in clinic.
Read More
Azacitidine Plus APR-246 Induces Promising Activity, Safety in TP53-Mutant MDS and AML
July 14th 2020In an interview with Targeted Oncology, Thomas Cluzeau, MD, PhD, discussed the findings from the phase 2 study of azacitidine plus APR-246 as treatment of patients with TP53-mutant myelodysplastics syndrome and acute myeloid leukemia. He also highlighted the next steps for this treatment regimen.
Read More
Phase 3 Study Confirms Benefit of Venetoclax/LDAC in Chemotherapy-Ineligible AML
July 3rd 2020A new randomized placebo-controlled study finds patients with acute myeloid leukemia who cannot undergo intensive chemotherapy have improved outcomes when given venetoclax in addition to low-dose cytarabine.
Read More
Managing Patients With Myeloid Malignancies During and After the Global COVID-19 Pandemic
June 24th 2020During the Virtual 25th Congress of the European Hematology Association (EHA), a group of physicians described their experiences and recommendations for managing patients with myeloid malignancies during the COVID-19 pandemic and after.
Read More
Azacitadine Plus Pevonedistat Shows Efficacy in MDS/CMML or LB AML
June 23rd 2020Mikkael Sekeres, MD, discusses a phase 2 study of pevonedistat plus azacitidine versus azacitadine monotherapy in patients with higher-risk myelodysplastic syndromes /chronic myelomonocytic leukemia or low-blast acute myelogenous leukemia.
Watch
Gemtuzumab Ozogamicin FDA Approval Extended to Pediatric CD33-Positive Acute Myeloid Leukemia
June 16th 2020The FDA expanded the approval of gemtuzumab ozogamicin to include an indication for the treatment of newly diagnosed pediatric patients with CD33-positive acute myeloid leukemia, which includes patients as young as 1 month old.
Read More
Eprenetapopt Plus Azacitidine Yields Promising Responses in High-Risk MDS/AML
June 14th 2020"The data from this ongoing trial of eprenetapopt with azacitidine continue to be very encouraging in these most difficult-to-treat [patients with] TP53-mutant MDS and AML, who not only have at least one TP53 mutation but the majority of whom also have high risk cytogenetic abnormalities,."
Read More
Expert Explores Potential Role of Doublets and Triplets in IDH1-Mutant Acute Myeloid Leukemia
June 11th 2020Courtney D. DiNardo, MD, discusses the current treatment landscape for patients with IDH1-mutated acute myeloid leukemia and how potential doublet and triplet combinations may play a role in this setting.
Watch